vimarsana.com
Home
Live Updates
MediciNova Announces Abstract Regarding Results of a Clinica
MediciNova Announces Abstract Regarding Results of a Clinica
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) - MediciNova (NASDAQ:MNOV)
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number:
Related Keywords
Tokyo ,
Japan ,
Chicago ,
Illinois ,
United States ,
American ,
Geoff Obrien ,
Gilbert Youssef ,
Oncology At Dana Farber Cancer Institute ,
American Society Of Clinical Oncology ,
Exchange Commission ,
Nasdaq ,
Physician At Harvard Medical School ,
Medicinova Inc ,
Standard Market ,
Tokyo Stock Exchange ,
Code Number ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Attending Physician ,
Harvard Medical School ,
Dana Farber Cancer Institute ,
Rapid Oral Abstract ,
Central Nervous System ,
Private Securities Litigation Reform Act ,